In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations

F. Dhainaut, 1 P.-O. Guillaumat, 1 H. Dib, 2 G. Perret, 1 A. Sauger, 1 C. de Coupade, 1 M. Beaudet, 1 M. Elzaabi 1 & L. Mouthon 2, 3

1 LFB Biotechnologies, Courtaboeuf, France
2 Université Paris Descartes, Faculté de Médecine, Institut Cochin, INSERM U1016, Paris, France
3 Université Paris Descartes, Pôle de Médecine Interne, hôpital Cochin, Centre de Référence pour les vascularites nécrosantes et la sclérodermie systémique, Assistance Publique-Hôpitaux de Paris, Paris

Received: 5 July 2012, revised 5 July 2012, accepted 9 July 2012, published online 25 September 2012

Objective To compare in vitro and in vivo biological and biochemical properties of five liquid intravenous immunoglobulin (IVIg) preparations licensed for therapeutic use in Europe.

Methods ClairYg® was compared in a blinded manner to four other liquid IVIg preparations licensed in Europe (Octagam®, Kiovig®, Gamunex®, Privigen®). Three batches of each preparation were tested, except for the IgG repertoires and the animal model.

Results Levels of anti-A and anti-B antibodies were lower in ClairYg® (0 Æ 11⁄0Æ11) relative to a positive EDQM standard and Octagam® (0Æ11/0Æ08) than in other preparations (0Æ33–0Æ69/0Æ42–0Æ46). IgG in ClairYg® recognized 365 and 416 protein spots in HEp-2 cell and Escherichia coli protein extracts vs. 230–320 and 402–842 protein spots, respectively, for IgG in other preparations. IgA content (301 vs. 165–820 ng/mg of IgG), Factor XI and Factor XII antigen (0Æ46 vs. 0Æ85–2Æ40 mU/mg of IgG and 7Æ8 vs. 2Æ0–4Æ62 IU/mg of IgG) C1q binding (0Æ42 vs. 0Æ67–1Æ89 arbitrary units) and C5a uptake (0Æ41 vs. 0Æ45–0Æ66% of activation) were lower in ClairYg® than in other preparations. Finally, intravenous infusion of ClairYg®, Gamunex® and Privigen® had no major effect on arterial blood pressure in spontaneously hypertensive rats.

Conclusions Our results evidence some differences in the biological and biochemical properties among licensed liquid IVIg preparations.

Key words: intravenous immunoglobulin, repertoires, liquid, factor XI, IgA, complement activation.

Introduction

Intravenous immunoglobulin (IVIg) are therapeutic preparations of normal human IgG obtained from pools of 20 000 to 40 000 healthy blood donors and thus contain a wide range of IgG reactivities [1]. Initially used as a replacement therapy for patients with primary and secondary immune deficiencies, IVIg preparations are now also used for the treatment of a number of autoimmune and/or systemic inflammatory diseases [2, 3]. The large donor pool ensures the diversity of IgG repertoire, and IVIg preparations are composed of a broad range of immune antibodies directed against pathogens and foreign antigens, natural autoantibodies and also anti-idiotypic antibodies [4].

An ideal immunoglobulin (Ig) preparation intended for clinical use should be safe and efficacious. Efficacy depends on suitable levels of protective antibodies against pathogens and the functional integrity of the Ig molecule. Plasma products for therapeutic use pose specific challenges in manufacturing to ensure biological activity and safety with
respect to potential contamination and transmission of disease-causing agents. As the manufacturing process, virus reduction methods, and final formulation and composition differ widely among these products, it is intuitive that safety and efficacy could also differ [5].

Intravenous immunoglobulin infusions are in most cases very well tolerated. Minor adverse effects such as hypertension, fever and chills, nausea, myalgias or headache are reported during IVlg infusion [6]. Severe complications are rare and include anaphylaxis, mainly due to immunization against IgA in patients with IgA deficiency, haemolysis due to the presence of haemagglutinins in IVlg preparations [7], acute renal failure [8], stroke and myocardial infarction [9]. Tolerance is actually a major issue, and a number of procedures have been proposed to improve the tolerance of IVlg preparations. However, very few studies are available that compare IVlg preparations obtained through different manufacturing processes for the presence of co-purified proteins and/or activation of biological cascades.

In the present work, we compared in a blinded manner three batches of five liquid IVlg preparations licensed in Europe including ClairYg®, a new liquid IVlg preparation obtained through ethanolic and caprylic acid precipitations [10], and provide evidence for some differences in the biological and biochemical properties among IVlg preparations tested.

Materials and methods

Intravenous immunoglobulin fractionation process

Clayrig® is a ready-to-use 5% liquid formulated polyvalent human IgG for intravenous administration fulfilling the current Note for Guidance on the Clinical Investigation of IVlg (CPMP/BPWG/94033/2007 rev.2) and the Core Summary of Product Characteristics for IVlg (CPMP/BPWG/94038/2007 rev.3). The purification of IgG from plasma is based on ethanolic and caprylic acid precipitations [10, 11]. To inactivate enveloped viruses, the protein solution is submitted to a solvent/detergent treatment. Then, IgG are purified by a succession of two chromatography steps. First, an anion exchange chromatography (Trimethyl-amoniumethyl chromatography) is performed, followed by an affinity chromatography that allows for the depletion of anti-A and anti-B haemagglutinins. To ensure viral safety, a second dedicated step, nanofiltration through a 20 nm pore size filter (Planova; Asahi Kasei Bioprocess, Tokyo, Japan), at acidic pH is performed. Finally, the IgG solution is stabilized in mannitol, glycine and polysorbate 80, adjusted at pH 4.8 and sterile-filtered before filling. Fractionation processes and virus removal steps used for other liquid IVlg preparations, Octagam® [12], Kiovig® [13], Gamunex® [14], Privigen® [15] are indicated in Table 1.

| Product     | Plasma fractionation | Ion exchange step | Viral inactivation               | Protein concentration, g/l | Formulation     |
|-------------|----------------------|-------------------|----------------------------------|----------------------------|----------------|
| ClaYig®     | Ethanol/caprylate     | Yes               | SD + nanofiltration              | 50                         | Liquid pH 4.8   |
| Octagam®    | Ethanol              | No                | SD + acidic pH                   | 50                         | Liquid acidic pH|
| Kiovig®     | Ethanol              | Yes               | SD + nanofiltration + acidic pH  | 100                        | Liquid acidic pH|
| Privigen®   | Ethanol/caprylate     | Yes               | SD + nanofiltration + acidic pH  | 100                        | Liquid acidic pH|
| Gamunex®    | Ethanol/caprylate     | Yes               | Caprylate + acidic pH            | 100                        | Liquid acidic pH|

Quantification of IgG in intravenous immunoglobulin preparations

Concentration of IgG in each batch was obtained by nephelometry using the standard method provided by Siemens (BNII, Saint Denis, France).

Quantification of IgA in intravenous immunoglobulin preparations by enzyme-linked immunosorbent assay

Flat-bottom microtitre plates (Dynex Technologies, ref: M129B, Chantilly, VA, USA) were coated with anti-alpha chains human IgA rabbit polyclonal antibodies (Dako, Glostrup, Denmark) in phosphate-buffered saline (PBS)
overnight at 4°C. After saturation with PBS + 1% bovine serum albumin (BSA from Sigma-Aldrich, ref A7030 Saint Louis, MO, USA), samples and normal human serum (Siemens Healthcare, Marburg, Germany) diluted in PBS + 0.1% Tween (Merck, ref: 8.22184.0500, Darmstadt, Germany) (PBS-Tween) + 0.1% BSA were incubated 2 h at 37°C. Then, a peroxidase-conjugated rabbit anti-human IgA antibody (Dako) was used as a secondary antibody and incubated 2 h at 37°C. After washing in PBS-Tween, 0-Phe-nylene-Diamine (OPD) (Sigma-Aldrich, ref: P-8412) was added in citrate–phosphate buffer at pH 5 and stopped with 2 M H2SO4. Optical density was measured as the ratio between the sample line slope and the positive control IVIG standard line slope. The standard curve equation is \( y = ax + b \), where ‘a’ is the slope value of the standard line and ‘b’ is the zero point corresponding to the assay background. As the sample equation is \( y' = d x + b \) and using known values of the sample’s MFI (y’) and IgG concentration (x’), the slope ratio was calculated as \( [(MFI-b)/\text{IgG concentration}]/a \).

**Dosage of monomers, dimers, polymers and fragments**

Measurements of fragment, monomer, dimer and polymer concentrations were performed using the European Pharmacopoeia method 01/2009: 0918.

**Dosage of haemagglutinins in intravenous immunoglobulin preparations**

**Flow cytometry**

Red blood cells (RBC) were collected on ethylenediamine-tetraacetic acid (EDTA) from patients belonging to A or B groups, all of them being Rh(D) negative. RBC were washed twice in NaCl 0.9% (Braun Medical ref: 0066570E Boulogne Billancourt, France) (centrifugation at 1730 \( g \) for 5 min in between washes). Two million RBC were distributed in a U-bottom microtitre plate (Greiner Bio-One, Ref: 650101, Kremsmünster, Austria) and 50 \( \mu l \) of a standard curve IVIG using an immunoglobulin positive control (EDQM n° Y0001152 : maximum permissible pharmacopoeial level in haemagglutination tests, Strasbourg, France) [16] or the diluted samples at a working concentration (in PBS pH 7.4 with 1% BSA) were added. Plates were incubated for 2 h at 37°C under shaking. Wash steps in PBS-BSA were repeated (3 \( \times \) 1 min at 770 g). A goat F(ab’)_2 anti-human IgG (Fc) phycoerythrin-conjugate (Beckman Coulter, Ref: PN IM0550, Villepinte, France) was used at a dilution of 1/20 in PBS-BSA. Plates were incubated 30 min at room temperature and protected from light. Wash steps were performed as described above. Each pellet was resuspended in 200 \( \mu l \) of PBS-BSA, and read with a Beckman Coulter Cytomics FC 500 flow cytometer (Beckman Coulter). The mean fluorescence intensity (MFI) of the positive control IVIG was plotted against IgG concentration (standard curve) for concentrations ranging from 0.23 to 30 g/l. Results were expressed as the ratio between the sample line slope and the positive control IVIG standard line slope. The standard curve equation is \( y = ax + b \), where ‘a’ is the slope value of the standard line and ‘b’ is the zero point corresponding to the assay background. As the sample equation is \( y' = d x + b \) and using known values of the sample’s MFI (y’) and IgG concentration (x’), the slope ratio was calculated as \( [(MFI-b)/\text{IgG concentration}]/a \).

**Haemolytic activity based on flow cytometry cell counts**

Peripheral blood was collected from patients of group A, B, AB and O, all Rh(D) negative, on heparin and washed twice in NaCl 0.9% (centrifugation at 1730 \( g \) for 5 min in between washes). RBC pellets were treated with papain according to the manufacturer instructions (Bio-Rad, Ref: 86594, Marnes-La-Coquette, France).

To ensure a good correlation between cell counts and viability, cells were stained with calcien acetoxymethyl ester (calcien-AM; Invitrogen-Fischer BioMol Ref: C3099, Illkirch, France) for 30 min at 37°C under shaking. After washing twice for 5 min at 480 g, U-bottom microtitre plates (Greiner Bio-One, Ref: 650101) were saturated with PBS, 1% BSA (Sigma-Aldrich, ref: A7030) (30 min at room temperature) and 2.5 \( \times \) 10^5 calcien-AM-red RBC were incubated in the presence of 50 \( \mu l \) of four IVIG dilutions (concentration ranging from 2 to 40 g/l). A standard curve using a positive IVIG international reference (EDQM n° Y0001152) [16] was added as well as internal controls, including 50 \( \mu l \) of cell suspension incubated either with 150 \( \mu l \) of water for injectable preparation for the total cell lysis or with 50 \( \mu l \) of PBS pH 7.4, 1% (w/v) BSA for spontaneous lysis (RBC lysis during the assay without addition of any IVIG) or 50 \( \mu l \) of 0+ serum tested as a positive internal control of the haemolytic reaction. Cells were incubated for 45 min at +37°C under shaking. Then, 100 \( \mu l \) of guinea-pig complement (Tebu-Bio, Ref: C300-0010, Le Perray en Yvelines, France) was added at working concentration in each well, except for the total cell lysis condition, and 1-h incubation at +37°C with shaking was performed before centrifugation (5 min at 480 g room temperature). RBC were analysed on a Beckman Coulter Cytomics FC 500 flow cytometer (Beckman Coulter). Results were expressed as a percentage of specific cell lysis.

**IgG antibody repertoire study**

**HEp-2 cell culture and protein extraction**

HEp-2 cells, a cell line derived from a human laryngeal carcinoma that represents the standard substrate for the detection of antinuclear antibodies [17], were obtained from EuroBio (Les Ulis, France) and cultured as described [18, 19]. Confluent cells were detached by use of 0.05% trypsin-EDTA (Gibco BRL, Invitrogen, Grand Island, NY, USA) and then washed twice with PBS and once in TBS.
Escherichia coli culture and protein extraction

*Escherichia coli* bacteria CIP 54:127 were cultured in Tryptic Soy Broth (Soybean-Casein Digest) medium (BD Bacto, Franklin Lakes, NJ, USA). A pellet of 19 billion bacteria was homogenized in a buffer containing 5 mM urea, 2 mM thiourea, 2% (w/v) 3-[(3-cholamidopropyl)dimethylamino]-1-propane sulfonate, 2% (w/v) SB 3–10, 40 mM Tris, 0.2% Bio-Lyte 3/10 and gently poured over V/V of 0.1-mm glass beads (BioSpec Products, Bartlesville, OK, USA) and then vigorously vortexed for 4 min. The supernatant was then ultra-centrifuged twice at 150 000 g. 25 min at 4°C. Proteins were quantified using the Bradford method and then extracts were aliquoted and frozen at −80°C until use.

**Two-dimension electrophoresis, electrotransfer and immunoblotting**

We used pH 3–10 and acrylamide gradient of 7–18% in all experiments, which allowed for studying a wide range of antigens of 10–250 kDa [22, 23]. Two-dimension gel electrophoresis, electrotransfer, immunoblotting, gel staining and image analysis of gels and 2-D blots were performed as recently reported [22, 24].

**Complement activation in intravenous immunoglobulin preparations**

**Evaluation of intravenous immunoglobulin binding to C1q**

Intravenous immunoglobulin binding to C1q was performed according to [25]. Briefly, flat-bottom low IgG affinity microtitre plates were incubated with 2 μg/ml human C1q (Calbiochem Ref: 204876 Fontenay sous bois, France), diluted in 0.1 M bicarbonate pH 9.6 buffer for 1 h at room temperature and then overnight at +4°C. After washing (3 × 5 min using PBS-Tween 0.1%), 300 μl of PBS pH 7.4 and 1% BSA (Sigma-Aldrich, ref: A7030) were incubated 1 h at room temperature. The washing procedure was repeated as described above and 100 μl of each sample dilution was incubated for 60 min at room temperature followed by 90-min incubation at +37°C. A total of eight different concentrations per sample were analysed starting from 1 g/l (1:2 dilutions in sample buffer: PBS-Tween 0.1%, 0.1% BSA, 0.1 M NaCl). After washing (3 × 5 min using PBS-Tween 0.1%), 100 μl of horse radish peroxidase (HRP) goat anti-human IgG (Fc γ-chain specific) conjugate (Jackson ImmunoResearch Ref: 109-035-098, West Grove, PA, USA) was incubated for 90 min at +37°C. After washing, revelation was stopped after 4–7-min incubation at room temperature with OPD (Sigma Ref: P8412) substrate, using 50 μl of 4 mM H₂SO₄. Results were expressed as a ratio between OD 492 units of the samples and the OD 492 nm of a human Ig biological reference preparation A (BRP A) reference, a Ph. Eur. reference standard (EDQM, catalogue code: H0990000, BRP batch 3).

**Complement activation assay by C5a release**

Human serum was obtained by pooling the serum of four healthy donors (AB group) and stored at −80°C. Before use, the serum was gently thawed at 4°C. Twenty μl of tested Ig at a concentration of 50 mg/ml was added to 80 μl of 0.04 M EDTA (Sigma-Aldrich Ref: E5134). After the incubation, C5a release in each test tube was assayed in triplicate by enzyme-linked immunosorbent assay (ELISA) method as previously described [26]. Flat-bottom microtitre plates were coated with 100 μl of anti-C5a (R&D systems Ref: MAB 2037, Lille, France) at 0.4 μg/ml in carbonate buffer 0.1 M pH 9.6 overnight at 4°C. After saturation with PBS + 1% BSA, samples and controls were diluted in saturation buffer, deposited in the plate and incubated 2 h at 20°C. The polyclonal biotinylated antibody (R&D systems Ref: BAF 2037) was then added and revealed with a peroxidase-conjugated streptavidin (DY998; R&D Systems). The absorbance was measured at 492 nm using an ELISA reader (Infinite M200; Tecan, Lyon, France). The percentage of complement activation was obtained according to the following formula: (Sample-Negative control)/(Maximum complement activation – Negative control) × 100. For each sample, the result corresponds to the mean obtained on the five independent activations. Acceptance criteria were applied: the positive control should be between 90% and 110% with an OD close to 1.3.

**Dosage of Factor XI and Factor XII antigens by enzyme-linked immunosorbet assay**

Flat-bottom microtitre plates were coated with goat anti-FXI or anti-FXII polyclonal antibodies (Cedarlane, Burlington, Ontario, Canada) in carbonate buffer 0.1 M pH 9.6 overnight at 4°C. After saturation with PBS + 2% BSA (Sigma-Aldrich ref: A7030), IVIg preparations and standard
(human plasma Unicalibrator, Stago, Asnières, France) diluted in PBS-Tween 0.1% (Merck ref: 822184/0500) + 0.1% BSA for FXI or + 2% BSA for FXII were incubated 1 h 30 min at 20°C. Then, peroxidase-conjugated anti-FXI or anti-FXII goat polyclonal antibodies were incubated 1 h 30 min at 20°C. After washing in PBS-Tween, OPD (Sigma-Aldrich ref: P-8412) was added in citrate–phosphate buffer at pH 5.0 for 2 min 30 s and then stopped with 2 M H2SO4. Optical density was measured at 490 nm. FXI Ag or FXII Ag concentrations were determined in each batch, and the results were expressed as ng of FXI or FXII per mg of IgG.

Assessment of haemodynamic effects of different intravenous immunoglobulin preparations in a rat model

The experiments were carried out using 42 14–15-week-old male SHR (Centre d’Elevage R. Janvier, B.P. 55, Le Genest-Saint-Isle, France). Hypertensive rats were anesthetized with sodium pentobarbital (60 mg/kg i.p.). After endotracheal intubation, rats were artificially ventilated (approximately 1 ml/100 g body weight and 60 strokes/min) with ambient air enriched with oxygen such as to maintain blood gas parameters (PO2, PCO2, pH) within physiological limits. One carotid artery and the penile vein were catheterized for blood pressure measurement and drug administration, respectively. Body temperature was maintained at 37–38°C by means of a heating pad.

The heparin-filled (100 IU/ml) catheter in the carotid artery was connected to a strain gauge manometer (model DT-XX, Ohmeda; GE Healthcare, Limonest, France) precalibrated with a mercury manometer.

Following an equilibration period of at least 15 min, necessary to obtain stable hemodynamic conditions, intravenous administration of each test/reference item was performed. Rats were injected either with the formulation buffer or one of the five IVIg preparations in a blinded manner. Nicardipine was obtained from Sigma. Haemodynamic parameters were continuously monitored and digitized at a sampling rate of 250–1000 Hz in each channel using HEM software (Notocord Systems, Croissy-Sur-Seine, France) and stored on the hard disk of a personal computer. Most of the experiments followed the same general procedures as described in [27].

Treatments were administered as an intravenous infusion under the following conditions (amendment to study Plan no.1): IVIg preparations concentrated at 10% and the formulation buffer were administered at 3·33 ml/kg/min over 3 min, whereas IVIg preparations concentrated at 5% were administered at 3·33 ml/kg/min over 6 min. The treatments above were blinded and included one control item group (formulation buffer) and five test item groups treated at 1000 mg/kg. Treatment unblinding was made at the end of the experiments. As a positive reference item group, six animals are treated with an intravenous infusion (2 ml/kg/min over 3 min) of nicardipine 30 μg/kg.

The intravenous route of administration was used to evaluate the cardiovascular effects of the different compounds since it is the intended clinical route.

The following parameters were measured: systolic arterial pressure (SAP, mmHg); diastolic arterial pressure (DAP, mmHg); mean arterial pressure (MAP, mmHg); heart rate (HR, beats/min). Haemodynamic parameters were measured at baseline (before injection, T0), at 3 (T₃), 6 (T₆), 10 (T₁₀), 15 (T₁₅), 30 (T₃₀) and 45 (T₄₅) min after the beginning of the intravenous infusion.

Statistical analysis

Data were presented using descriptive statistics (n, mean, standard deviation (SD), SEM, minimum, maximum) for raw data, and changes from baseline (delta and delta %) and graphs illustrating means ± SEM of each group over time were provided. In the case of experimental data obtained in rats, for each parameter, homogeneity of baseline values (T₀) between the seven groups was tested using a one-way ANOVA. For each parameter, changes from baseline value (delta) at each measurement time were compared using a two-way ANOVA (group, time) with repeated measurements over time.

Results

Anti-A and anti-B haemagglutinins

ClairYg® and Octagam® had a low level of anti-A and anti-B haemagglutinins, whereas other IVIg preparations tested expressed threefold to sixfold higher levels of anti-A and anti-B haemagglutinins (Fig. 1a). Specific lysis of human RBC from A, B and AB Rh(D) negative groups varied and at a lower level Privigen® and ClairYg®, than with the other three IVIg preparations (Fig. 1b).

Analysis of IgG antibody repertoires in intravenous immunoglobulin preparations

The five IVIg preparations were tested with a protein extract of HEp-2 cells enriched with nuclear proteins (Fig. 2). IgG in ClairYg® recognized 365 protein spots vs. 230–330 protein spots, respectively, for IgG in other preparations (Table 2). In fact, Octagam® and at a lower level Privigen® recognized a greater number of protein spots in isoelectric pH between five and seven, and Octagam® and ClairYg® recognized a...
higher number of proteins of high molecular weight than other preparations. The five IVIg preparations were also tested for IgG reactivity with a protein extract of *E. coli* (Fig. 3). IgG in ClairYg recognized 416 protein spots vs. 402–842 protein spots for IgG in other preparations (Table 2). ClairYg recognized a lower number of protein spots of high isoelectric pH than other IVIg preparations, whereas Octagam expressed a lower number of high reactivity spots in the low isoelectric pH than other IVIg preparations (Fig. 3). Thus, the repertoires of IgG reactivities were markedly heterogeneous among the five IVIg preparations tested.

Quantification of IgA in intravenous immunoglobulin preparations

Quantification of IgA varied widely among the five IVIg preparations tested. Privigen had a lower level of IgA compared with ClairYg and Gamunex, whereas IgA content was higher in Kiovig and Octagam (Table 3).

Dosage of monomers, dimers, polymers and fragments

Limited differences were observed among IVIg preparations regarding the content of polymers (Table 3). Kiovig and Privigen had the highest level of dimers, whereas Gamunex content in dimers was the lowest. Kiovig contained the least monomers, whereas ClairYg, Octagam and Gamunex had the highest monomer content. Finally, the lowest content in fragments was detected in ClairYg (Table 3).

Quantification of Factor XI and Factor XII antigens by enzyme-linked immunosorbent assay

Concentrations of Factor XI and Factor XII antigen varied widely among the five IVIg preparations tested. Factor XI and Factor XII antigen (0–46 vs. 0–85–240 mU/mg of IgG and 7.8 vs. 20.0–46.2 IU/mg of IgG with one Unit
corresponding respectively to 5 and 30 µg/mL) were lower in ClairYg® than in the four other IVIg preparations (Fig. 4). The highest amounts of Factor XI and Factor XII were detected in Octagam® and Kiovig® preparations.

Complement activation in intravenous immunoglobulin preparations

Complement activation varied among the various IVIg preparations tested. Thus, C1q binding varied from one to almost five times, whereas C5a release varied from one to two times. C1q binding (0.42 vs. 0.55–1.89) (Fig. 5a) and C5a release (14% vs. 21–35%) (Fig. 5b) were lower in ClairYg® than in other preparations. C1q binding and C5a release were the highest in Octagam® and Gamunex®.

Assessment of haemodynamic effects of intravenous immunoglobulin preparations in a rat model

Intravenous infusion of ClairYg®, Gamunex® and Privigen® had no major effect on arterial blood pressure in spontaneously hypertensive rats whereas Octagam® and Kiovig® transiently decreased arterial blood pressure (Fig. 6). Nicardipine (30 µg/kg, intravenous infusion), used in this study as a positive reference item, displayed a clear hypotensive activity. No major effect was observed on HR by the IVIg preparation tested (data not shown).

Discussion

In this work, we compared the biological characteristics of five liquid IVIg preparations licensed in Europe and observed biochemical differences among these IVIg preparations for anti-A and anti-B haemagglutinins, IgG antibody repertoires, IgA and factor XI and factor XII content and complement activation.

The amount of anti-A and anti-B haemagglutinins and the induction of haemolysis differed notably among the five IVIg preparations tested. Since the direct haemagglutination method still appears variable from one IVIg preparation to another and from one laboratory to another [16], we decided to use the cytometry technique applied to anti-A/B determination levels, which appears more reliable and accurate. Interestingly, ClairYg® and Octagam® had a lower level of anti-A and anti-B haemagglutinins than other IVIg preparations. The manufacturing process of ClairYg® is based essentially on caprylic acid precipitation. Since after

Table 2 Number of IgG reactivities expressed in different intravenous immunoglobulin (IVIg) preparation towards Hep-2 cells and Escherichia coli antigens

| IVIg preparations | Source of antigens | Hep-2 | E. coli |
|--------------------|------------------|-------|---------|
| ClairYg®           |                  | 365   | 416     |
| Octagam®           |                  | 330   | 653     |
| Kiovig®            |                  | 288   | 842     |
| Gamunex®           |                  | 321   | 402     |
| Privigen®          |                  | 230   | 458     |
caprylic acid precipitation anti-A and anti-B haemagglutinin levels were higher than expected, a specific affinity chromatography for anti-A and anti-B haemagglutinin depletion was added in the process, explaining the very low levels of haemagglutinins detected in ClairYg®/C210. Interestingly, Gamunex®/C210 and Privigen®/C210, the two other IVIg preparations using a specific caprylic acid precipitation step tested in the present work, for which there is no mention of haemagglutinin depletion in the manufacturing process, had high levels of anti-A and anti-B haemagglutinins.

Although IVIg products are approved as safe and effective and meet European standards recommending low levels of anti-A and anti-B haemagglutinins (<1/64), the passive transfer of IgG antibodies against the blood group A, B and RhD antigens has been associated with adverse reactions in recipients, including haemolysis and anaemia in severe cases [7]. Since it is difficult to predict the occurrence of haemolysis, detection of haemolytic reaction could lead to reconsider continuing IVIg treatment [7, 28].

Analysis of repertoires of IgG reactivities directed at self and bacterial antigens [22, 23] identified notable differences among IVIg preparations in terms of number of IgG reactivities and target antigens recognized. Based on the results obtained with a commensal and pathogenic bacteria,

---

**Table 3** Comparison of biological and biochemical properties among five licensed liquid intravenous immunoglobulin preparations

| Components | Anti-A* | Anti-B* | IgA (ng/mg IgG) | Polymers (%) | Dimers (%) | Monomers (%) | Fragments (%) | C1q (AU) | C5a (%) |
|------------|---------|---------|-----------------|--------------|------------|--------------|--------------|----------|----------|
| ClairYg®   | 0.11 ± 0.03 | 0.11 ± 0.01 | 301 ± 148 | 1.3 ± 0.2 | 7.0 ± 0.3 | 91.2 ± 0.1 | 0.5 ± 0.1 | 0.42 ± 0.04 | 14 ± 1.5 |
| Octagam®   | 0.11 ± 0.01 | 0.08 ± 0.03 | 820 ± 170 | 1.0 ± 0.1 | 6.8 ± 1.4 | 91.6 ± 1.4 | 0.6 ± 0.1 | 1.66 ± 0.14 | 32 ± 1.7 |
| Kiovig®    | 0.33 ± 0.03 | 0.42 ± 0.05 | 500 ± 46 | 1.2 ± 0.2 | 11.2 ± 1.3 | 86.8 ± 1.5 | 0.7 ± 0.1 | 0.67 ± 0.22 | 26 ± 1.0 |
| Privigen®  | 0.64 ± 0.01 | 0.46 ± 0.02 | 165 ± 46 | 0.7 ± 0.1 | 8.8 ± 0.7 | 89.5 ± 0.8 | 1.1 ± 0.2 | 0.55 ± 0.11 | 21 ± 1.0 |
| Gamunex®   | 0.69 ± 0.04 | 0.46 ± 0.03 | 385 ± 17 | 0.9 ± 0.1 | 5.1 ± 0.2 | 93.0 ± 0.2 | 1.0 ± 0.1 | 1.89 ± 0.37 | 35 ± 2.1 |

AU, arbitrary unit.

Data are mean ± SD (n = 3).

*Ratio between tested sample and EDQM positive control Y0001152.

bPercentage of activation vs. maximum complement activation using LPS.

---

© 2012 The Author(s)

Vox Sanguinis © 2012 International Society of Blood Transfusion

Vox Sanguinis (2013) 104, 115–126
E. coli and the cell line usually used to detect anti-nuclear antibodies, Hep-2 cells, we provide evidence that ClairYG®/C210 expresses a large range of antibody reactivities directed against bacteria or autoantigens. A number of factors can influence the antibody content of IVIg preparations including the donors that participate to the pool of plasma and the manufacturing process. Thus, depending on their genetic background, the geographic area where the donors live and the type of environmental antigens they encountered, the antibody specificities contained in IVIg preparations may vary, contributing to explain the differences in repertoires of reactivities directed at microbial antigens and/or autoantigens contained in IVIg preparations [4]. The manufacturing process may also influence IgG antibody reactivity, mainly through differences in the pH level, temperature and sodium concentration [29]. Thus, comparing IVIg preparations obtained through Cohn or propiolactone fractionation processes, we observed that the protein spots recognized by IgG in propiolactone-IVIg represented the core set of self-antigens targeted by IVIg and that an acidic pH step artificially enlarges the repertoire of self-reactive IgG [24]. However, no clinical interpretation can be made from these data, since all of the IVIg preparations tested had demonstrated efficacy in substitution and immunomodulation in patients on the basis of clinical studies despite notable differences in IgG repertoires among these IVIg preparations.

The IgA content, which potentially affects the risk and intensity of adverse events associated with administration of IVIg preparations, including anaphylactic shock, varies widely from one to another [30], depending on the purification process. For ClairYG®, the anion exchange chromatography step is dedicated to the reduction of IgA and IgM levels, although other processes such as the ability of lectin jacalin to selectively bind IgA1 subclass have been utilized in the past to deplete IgA [31].

Limited differences were observed among IVIg preparations regarding the content of dimers and polymers. Enrichment of IVIg in dimers was found to be associated with an increase in the antibody activity against

---

**Fig. 4** Quantification of FXI Antigen and FXII Antigen in five liquid intravenous immunoglobulin products using enzyme-linked immunosorbent assay. Three batches per product were tested in duplicates. Results were expressed as mean ± SD of FXI or FXII concentration in ng per mg of IgG.

---

**Fig. 5** (a) Evaluation of classic complement activation pathway by C1q-binding intravenous immunoglobulin (IVIg) products. Wells were coated with human C1q and incubated with five IVIg preparations (three batches each) at eight concentration points. C1q binding was assessed using an anti-human IgG antibody (γ-chain specific). Results are expressed as the mean and SD of IgG relative binding to C1q. (b) Evaluation of whole complement activation. After incubation of IVIg in diluted human serum at 37°C, the C5a release was assayed by enzyme-linked immunosorbent assay. Results represent the percentage of C5a release related to a maximal release obtained with LPS and are expressed as mean and SD on three batches of each IVIg.
self-antigens and suggests that therapeutic preparations of IVIg enriched in dimmers might exert high potential immuno- modulatory activity in vivo [32]. However, these data remain controversial [33], mainly because it is known that the dimer level is dependent on pH formulation [34]. In addition, a number of other factors can influence the presence of fragments in IVIg preparations, among which the use of proteases such as pepsin and/or the presence of residual plasmin in the manufacturing process [35].

The manufacturing process does not only influence the antibody specificities and isotypes contained in IVIg preparations, but also the amount of non-immunoglobulin factors contained in IVIg.

Interestingly, we identified that concentrations of factor XI and factor XII antigens varied a lot between the five preparations tested, and the content in factor XI was the highest in Octagam® and Kiovig®. Interestingly, in the present work, Factor XI and Factor XII antigen concentrations were lower in ClairYg® than in the four other IVIg preparations. Because the addition of small amounts of activated factor XI to plasma can lead to production of significant amounts of thrombin, it has been suggested that activated factor XI (FXIa), which is present in IVIg preparations, could contribute to the in vivo risk of thrombosis after IVIg therapy [36]. In a recent work, the amount of factor Xla detected in the product correlated with the manufacturer, suggesting that variations in the manufacturing process or plasma source affect the level of factor XI in the IVIg product [36]. Importantly, the high content in factor Xla of IVIg preparations has been associated with increased risk of thromboembolic events, including stroke, pulmonary embolism, deep venous thrombosis or myocardial infarction [36, 37]. In another recent work, Kallikrein and FXIa were identified as the major contaminants with respect to coagulant activity in IVIg preparations [37]. FXIa is highly procoagulant, with the highest level in thromboembolic event–associated IVIg. Since the non-activated partial thromboplastin time unambiguously identified FXIa procoagulant activity in IVIg, its implementation as a release test would improve the safety of IVIg [37]. Although the low level of contaminating coagulation factors detected in ClairYg® may contribute to good clinical tolerance, it will need to be confirmed by the analysis of the incidence of serious adverse effect reported after IVIg injection, particularly thromboembolic events.

We have observed that complement activation varied among the various IVIg preparations tested and that C1q binding and C5a releases were lower in ClairYg® than in other preparations. The initially perceived adverse effects, stemming from complement activating aggregated IgG, including fever, chills and hypotension [38], had the effect of slowing down widespread introduction of IVIg therapy in the late 1970s, although these adverse effects have now been eliminated with amendment of the appropriate manufacturing steps. However, the capacity of different IVIg preparations to scavenge activated C3 and thereby inhibit complement activation varies between the products [39].

Finally, intravenous infusion of ClairYg®, Privigen® and Gamunex® had no major effect on blood pressure in spontaneously hypertensive rats, whereas infusion of Kiovig® and Octagam® transiently decreased arterial blood pressure. It has been proposed that polymers, complement activation and bradykinin generation might contribute to hypotension after IVIg infusion [38, 40], which is in agreement with our
results in the case of Octagam® but not in the case of Gamunex®. These data provide evidence for potential heterogeneity in the induction of adverse reactions among licensed IVIg preparations.

Conclusion

We provide evidence for the heterogeneity of biological properties including IgA, haemagglutinins, Factor XI, Factor XII concentrations, repertoires of antibodies and complement activation among five liquid IVIg preparations. These data demonstrate that the origin of plasma and the type IVIg purification processes both contribute to obtain a pharmaceutical product with distinct biochemical and physiological properties, although all IVIg preparations have demonstrated efficacy in patients with immune deficiency and systemic and/or autoimmune diseases.

Acknowledgements

We thank C. Souvannavong, J. Leberichel, B. Bodenant for their technical expertise and S. Boyer for the codification and distribution of the different samples in each analytical laboratory.

Funding

The work was funded by LFB biotechnologies. FD, POG, GP, AS, CDC, MB and ME are employed by LFB biotechnologies. HD received a grant from AMPLI (‘Avenir Mutualiste des Professions Libérales & Indépendantes’) and ARMIIC (‘Association pour le Recherche en Médecine Interne et en Immunologie Clinique’). LM has relationships with drug companies including Actelion, CSL Behring, Cytheris, GSK, LFB Biotechnologies, Lilly, Octapharma and Pfizer. Relationships include consultancy service and membership of scientific advisory boards, and being an investigator in trials involving Actelion, CSL Behring and Pfizer. ARMIIC received funding from LFB for performing the two-dimensional immunoblotting and for implication of LM to drafting of the manuscript.

Authors’ contributions

FD designed and coordinated the study and participated to manuscript drafting; POG supervised experiments for the in vivo rat hypotension model; HD performed and interpreted the 2D immunoblotting experiments; G. Perret was responsible for C5a analysis; A. Sauger was responsible for measuring Factors XI and XII antigens as well as IgG and IgA concentrations; CDC was responsible for the anti-A and anti-B testing and C1q binding analysis; MB was responsible of HPLC analysis; ME assisted with the overall design of the study and participated in manuscript drafting. LM supervised the IgG repertoires analysis, participated in study design, coordinated the study to data interpretation and drafted the manuscript. All authors read and approved the final manuscript.

References

1 Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107–116
2 Mouthon L: Indications for intravenous immunoglobulins. Presse Med 2006; 35(4 Pt 2):714–719
3 Hartung HP, Mouthon L, Ahmed R, et al.: Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol 2009; 158(Suppl 1): 23–33
4 Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmunity and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747–755
5 Gelfand EW: Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006; 6:592–599
6 Caress JB, Kennedy BL, Eickman KD: Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010; 9:971–979
7 Kahwaji J, Barker E, Pekpowitz S, et al.: Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4:1993–1997
8 Dickenmann M, Oettl T, Mihahtsch MJ: Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51:491–503
9 Baba R: Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov 2008; 3:141–144
10 Steinbuch M, Audran R: The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys 1969; 134:279–284
11 Kistler P, Nitschmann H: Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7:414–424
12 Biesert L: Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996; 14(Suppl 15):S47–S52
13 Teschner W, Butterweck HA, Auer W, et al.: A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Vox Sang 2007; 92:42–55
14 Lebing W, Remington KM, Schreiner C, et al.: Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003; 84:193–201
15 Stucki M, Boschetti N, Schafer W, et al.: Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008; 36:239–247

© 2012 The Author(s)
Vox Sanguinis © 2012 International Society of Blood Transfusion
Vox Sanguinis (2013) 104, 115–126
22 Servettaz A, Guilpain P, Camoin L, et al.: Identification of target antigens of antiendothelial cell antibodies in healthy individuals and patients with autoimmune diseases. Ann N Y Acad Sci 2007; 1109:538–549
24 Bussone G, Dib H, Dimitrov JD, et al.: Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. Proteomics 2009; 9:2253–2262
25 Stanilova SA, Slavov ES: Comparative study of circulating immune complexes quantity detection by three assays – C1q-ELISA, C1q-ELISA and anti-C3 ELISA. J Immunol Methods 2001; 253:13–21
26 Bergh K, Iversen OJ: Production of monoclonal antibodies against the human anaphylatoxin C3a des Arg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C3a des Arg in plasma. J Immunol Methods 1992; 152:79–87
27 Kroez M, Kanzy EJ, Gronski P, et al.: Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003; 31:277–286
28 Daw Z, Padmore R, Neurath D, et al.: Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48:1598–1601
29 Lahrousse H, Adib-Conquy M, Avrameas S: Effects of pH or ionic strength on the reactivities of mono- and polyspecific IgG antibodies. Res Immunol 1994; 145:541–552
30 Mishah S: Intravenous immunoglobulin in the Guillain-Barre syndrome. Products with low IgA content may be used in patients with total IgA deficiency. BMJ 1996; 313:1400
31 Dovzeyenski N, Velickovic Z, Tolic L, et al.: Contamination of IgG preparations for intravenous use with IgA. II. Removal of IgA1 from IgG preparation using affinity chromatography on lectin jacalin columns. Srp Arh Celok Lek 1994; 122(Suppl 1):51–52
32 Vassilev TL, Bineva IL, Dietrich G, et al.: Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995; 8:405–413
33 Bruley-Rosset M, Mouthon L, Chanseau Y, et al.: Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases. Lab Invest 2003; 83:1013–1023
34 Ahrer K, Buchacher A, Iberer G, et al.: Detection of aggregate formation during production of human immunoglobulin G by means of light scattering. J Chromatogr A 2004; 1043:41–46
35 Skvaril F, Gardi A: Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis J 1988; 5(Suppl):S43–S48
36 Wolberg AS, Kon RH, Monroe DM, et al.: Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65:30–34
37 Eschede M, Breitner-Ruddock S, Gross S, et al.: Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012; 102:40–46
38 Misbah SA, Chapel HM: Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9:254–262
39 Spycher M, Matozan K, Minnig K, et al.: In vitro comparison of the complement-scapening capacity of different intravenous immunoglobulin preparations. Vox Sang 2009; 97:348–354
40 Medgyesi GA, Kovacs J, Fust G, et al.: Safety aspects of intravenous immunoglobulins. Immunol Invest 1988; 17:121–133